CLINICAL_TRIALS
trial_result
· 2013-05-01
Clinical Trial Update: Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle [Phase 3]
Summary
A Phase 3 safety study comparing Besivance (besifloxacin ophthalmic suspension) 0.6% to vehicle in bacterial conjunctivitis, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bausch & Lomb Incorporated | Conditions: Bacterial Conjunctivitis | Phase 3 | Status: COMPLETED | Results posted: 2013-05-01